37 results about "Riboflavinum" patented technology

A rinsing solution for photodynamic disinfection, in particular oral disinfection, including, at least one photosensitiser from the group comprising riboflavin 5′-phosphate sodium in a proportion of 0.2 to 0.6 wt. % and a photosensitiser other than riboflavin 5′-phosphate sodium in a proportion of 0.001 to 0.05 wt. %, at least one viscosity modulator from the group comprising glycerol in a proportion of 1.0 to 5.0 wt. % and hyaluronic acid sodium salt in a proportion of 0.01 to 0.3 wt. %, at least one biofilm inhibitor from the group comprising xylitol in a proportion of 7.0 to 25.0 wt. %, L-arginine in a proportion of 0.01 to 0.5 wt. % and urea in a proportion of 0.5 to 3.0 wt. %, with the remainder on a water base.

The application belongs to the technical field of bioengineering, and particularly relates to application of a riboflavin kinase / FMN adenosine transferase truncated protein and a mutant thereof in FMN synthesis. The application obtains a mutant with improved riboflavin kinase enzyme activity by truncating and mutating RibFM-1, and uses the mutant in FMN production. The FMN yield of the strain containing the truncated protein gene is increased by 49.14%, 33.97%, 43.58%, 22.42%, 76.31% and 113.70% respectively compared with the strain containing the non-truncated gene. It can be seen that the riboflavin kinase / FMN adenosine transferase can significantly improve the yield of FMN after being truncated or mutated, and has a wide application potential in FMN industrial production.

Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.

The present application belongs to the field of photochemical therapy, and particularly relates to a method for photochemical treatment of riboflavin based on multi-wavelength LED and application thereof in treatment of graft-versus-host disease. The present application selects different wavelength LED combinations as light sources to optimize the riboflavin photochemical method, controls the light intensity at 1000-25000 μW / cm², controls the irradiation time at 5-15 minutes, and controls the riboflavin concentration at 20-150 μM, thereby significantly improving the photochemical reaction effect. The method can efficiently induce PBMC apoptosis in a plasma environment, significantly reduces the levels of key pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-γ, and has no significant influence on platelets, hemoglobin and blood clotting function, thereby providing a safe and controllable new cell preparation method for GVHD treatment.

Provided herein are compositions and methods for measuring the levels of flavins (e.g., in biological samples). In particular, provided herein are modified biotin-riboflavin conjugates and uses thereof (e.g., to measure flavin levels).

An application of a riboflavin-loaded microneedle patch in the preparation of materials for treating keratoconus is disclosed. This microneedle patch, shaped like a contact lens, adheres comfortably to the ocular surface, with its base conforming to the conjunctiva and the microneedle array precisely oriented towards the cornea. Within a short period of application, the microneedles puncture the corneal epithelium and rapidly dissolve simultaneously, achieving efficient delivery of riboflavin to the stroma. Meanwhile, the dissolved base forms a protective film on the ocular surface. This microneedle patch enables safe and efficient delivery of riboflavin across the ocular barrier, effectively avoiding various risks associated with epithelial removal in traditional corneal cross-linking procedures, preventing large-area epithelial defects, preserving barrier integrity, and reducing the risk of postoperative infection. Furthermore, this microneedle patch achieves precise enrichment of riboflavin within the corneal stroma, overcoming the concentration uncertainty caused by passive diffusion after epithelial defects, which relies on traditional eye drops. This ensures that the riboflavin concentration in the stroma reaches the optimal photosensitization threshold, thereby maximizing cross-linking efficiency and demonstrating significant application potential in the clinical treatment of keratoconus.

The present disclosure relates to a plaque disclosing composition containing riboflavin 5-phosphate sodium, a method for disclosing a plaque, wherein the plaque is an acquired pellicle, and a method for collecting and analyzing an information about the amount and characteristics of dental plaque by analyzing the color and intensity of fluorescence emitted by riboflavin 5-phosphate sodium for effective treatment of dental plaque even at an early stage.

The invention discloses an S288C riboflavin kinase mutant and application thereof, and belongs to the technical field of riboflavin kinase. The amino acid sequence of the S288C riboflavin kinase mutant disclosed by the invention is as shown in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6. The original riboflavin kinase is subjected to site-directed mutagenesis and screening to obtain the S288C riboflavin kinase mutant which has high activity, high alkali resistance and high selectivity and is suitable for industrial application, and the S288C riboflavin kinase mutant has a wide application prospect when being used for preparing FMN.

The invention discloses Escherichia coli for fermentation production of riboflavin anti-bacteriophage, and belongs to the technical field of microorganisms. Receptor genes of bacteriophages are excavated through co-evolution of bacteriophages T1, T7, vBEcoMP251 and vBEcoMP255 and escherichia coli strains, the resistance of escherichia coli to the bacteriophages is enhanced by knocking out screened bacteriophage receptors on the genome level, and meanwhile, defense systems Gabija and KELM with the ability of resisting bacteriophages JNUWH1 and JNUWD and defense systems Shedu and Septu with the ability of resisting bacteriophages T4 are obtained through screening. Gene is integrated to a genome to strengthen the resistance of escherichia coli to bacteriophage, construction of the anti-bacteriophage chassis cell is completed, meanwhile, genes lacI, pfkA, edd and eda are knocked out, the anti-bacteriophage escherichia coli chassis cell for fermentation production of riboflavin is obtained, and a certain application prospect is achieved.

The invention discloses a riboflavin biosensor construction method based on an RNA element, and belongs to the field of synthetic biology. On the basis of an FMN riboswitch and a foothold switch, an expression platform of a wild type FMN riboswitch is artificially modified, a sensitive riboswitch biosensor is constructed, and efficient detection of the riboflavin concentration is achieved; the fluorescence value of a riboswitch of the detection strain constructed by the method under the riboflavin concentration of 1 mmol / L is 4.3 times of the fluorescence value under the riboflavin concentration of 0 mmol / L.

The application provides a resiquimod prodrug and a preparation method and application thereof. The resiquimot prodrug comprises a carrier and a riboflavin derivative loaded on the carrier. The carrier is obtained by bonding R848-TK and mPEG-PHEA. b The application uses R848 NPs as a carrier to physically load a liposoluble riboflavin derivative, and is used for constructing an ultrasound-activated resiquimot prodrug. The riboflavin derivative is a liposoluble substance, can be activated under ultrasound conditions, and then generates 1 O2, is used for cutting the TK bond, thereby releasing the active drug R848. The application can effectively enhance the tumor selectivity of the drug and realize a time-space controllable precise treatment by preparing a more specific ultrasound-activated resiquimot prodrug.

The application provides a Saccharomyces cerevisiae for fermentative production of riboflavin, a microbial inoculum, a fermentation method and application thereof, and relates to the field of microbial fermentation. The application provides a Saccharomyces cerevisiae XF-GT, with a preservation number of CCTCC NO: M20242498, which has been preserved in the China Center for Type Culture Collection on November 11, 2024. The application adopts the Saccharomyces cerevisiae XF-GT for fermentative production of riboflavin, optimizes carbon sources and nitrogen sources, and combines with medium feeding culture to make the riboflavin yield reach 45.97 g / L after 96 h of fermentation, and the conversion rate reach 12.47%, so that the fermentation production method has high yield, stable process and is beneficial to industrial production.

A fluorescent examination liquid containing water, riboflavin or rhodamine (B) as a fluorescent pigment dissolved in the water, and a deterioration preventive agent for preventing deterioration of the fluorescent pigment due to light, the deterioration preventive agent containing a p-hydroxybenzoic acid ester.

This invention belongs to the field of ophthalmic medication technology, specifically relating to a lyophilized formulation, dispersion method, and dispersion formulation of a metalloriboflavin composite nanomaterial. This invention discovers the -HPO4 group on riboflavin sodium phosphate. ‑ Metalloriboflavin composite nanomaterials obtained by coordinating metal ions on the group exhibit excellent transepithelial riboflavin delivery capabilities. Their transepithelial corneal crosslinking effect is comparable to that of classic corneal crosslinking schemes involving epithelial ablation. Further screening of the effects of preservation methods and dispersants on their transepithelial riboflavin delivery capabilities revealed that materials prepared by lyophilization and those dispersed in deionized water both retained the material's excellent transepithelial riboflavin delivery capabilities, comparable to the crosslinking effects of clinical epithelial corneal ablation. This has significant research implications for the long-term preservation, industrial production, and even future clinical applications of metalloriboflavin composite nanomaterials.

The application discloses an EC riboflavin kinase mutant and application thereof, and belongs to the technical field of riboflavin kinase.The amino acid sequence of the EC riboflavin kinase mutant is shown in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6.The EC riboflavin kinase mutant with high activity, high alkali resistance, high selectivity and suitable for industrial application is obtained by site-directed mutagenesis and screening of the original riboflavin kinase, and the mutant can be used for preparing FMN and has wide application prospects.

The application of an alkyl radical initiator in the preparation of a scleral collagen cross-linking drug and an oxygen-independent scleral collagen cross-linking method, which utilizes an alkyl radical initiator to cross-link type I collagen solution and scleral tissue, compared with the ultraviolet light / riboflavin cross-linking method, the reaction does not depend on the participation of oxygen, and may be more suitable for the sclera under the hypoxic state of myopia, and compared with the chemical cross-linking method, the cross-linking reaction is easier to control. The alkyl radical-induced collagen cross-linking has improved in terms of anti-enzyme degradation performance, thermal stability and biomechanical performance.

The application discloses a S288C riboflavin kinase mutant and application thereof, and belongs to the technical field of riboflavin kinase.The amino acid sequence of the S288C riboflavin kinase mutant is shown in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6.The S288C riboflavin kinase mutant with high activity, high alkali resistance, high selectivity and suitable for industrial application is obtained by site-directed mutagenesis and screening of the original riboflavin kinase, and the S288C riboflavin kinase mutant is used for preparing FMN, which has wide application prospects.

The invention relates to an elsholtzia and ginseng composite peptide special diet for improving cardiovascular and cerebrovascular diseases and microcirculation disturbance and a preparation method thereof. The special diet comprises the following components: 5-15% of small molecule peptide; 18-65% of a plant extract; 0.1 to 3 percent of gamma-aminobutyric acid; 0.01 to 1 percent of N-acetylneuraminic acid; 0.005% to 0.1% of thiamine; 0.001 to 0.05 percent of riboflavin; and the balance of auxiliary materials. Wherein the plant extract comprises at least one of elsholtzia, rhizoma zingiberis and ginseng. According to the scheme provided by the invention, the elasticity and permeability of blood capillaries can be improved, microcirculation can be improved, blood fat can be reduced, and cardiovascular and cerebrovascular diseases can be effectively prevented and relieved.

The invention discloses an engineering strain with high yield of echinocandin B as well as a construction method and application of the engineering strain, and belongs to the technical field of gene engineering. According to the invention, wild aspergillus nidulans BGCm5 is modified by a CRISPR / nCas9-CBE (clustered regularly interspaced short palindromic repeats / nCRas9-CBE (clustered regularly interspaced short palindromic repeats / nCRas9-CBE) technology, so that nutritional deficient strains of NHEJ (NkuA mutation), pyridoxine (PyroA mutation) and riboflavin (RiboB mutation) are obtained. And then, introducing an orthogonal Lox site by utilizing CRISPR / Cas9, and constructing a chassis cell. Through a Cre / LoxP and Cre / Lox2272 recombination system, a combined overexpression cassette of aniF, aniF 2, aniG, aniH, aniI, aniK and odeA genes is integrated into a genome, a series of engineering strains are obtained, and the production efficiency is remarkably improved.

This invention provides a soluble microneedle patch for ultraviolet light scleral crosslinking and its preparation method, belonging to the field of biomedical materials. The soluble microneedle patch for ultraviolet light scleral crosslinking comprises microneedles and a base layer, wherein the microneedles and base layer comprise polyvinyl alcohol and oxygen-carrying riboflavin liposomes. Applying the soluble microneedle patch of this invention eliminates the need for extensive incision of the bulbar conjunctiva, thereby shortening surgical time, reducing surgical damage, alleviating patient discomfort, and increasing surgical safety. Secondly, the inventors have customized the microneedle height according to different scleral thicknesses, ensuring safe and minimally invasive scleral puncture, further enhancing surgical safety. Finally, the application of the soluble microneedle patch automates riboflavin perfusion, eliminating the need for frequent manual instillation of riboflavin solution, simplifying surgical procedures, and improving surgical efficiency.

The application belongs to the technical field of eye medication, and specifically designs a metal riboflavin nanomaterial and a trans-epithelial corneal cross-linking preparation. The metal riboflavin (nRfpM) nanomaterial is obtained by coordinating modification of metal ions on the -HPO4- group of riboflavin sodium phosphate. n+ The lipophilicity of the nRfpM nanomaterial is greatly improved due to the coordination of the -HPO4- group for improving the hydrophilicity of the Rfp molecule, and the trans-epithelial delivery capacity of the product nRfpM nanomaterial is further improved, so that the trans-epithelial corneal cross-linking effect of the obtained product is greatly improved and can be comparable to the clinical de-epithelial corneal cross-linking effect, thereby providing a new type of reagent for trans-epithelial corneal cross-linking and having important clinical application prospects.

The utility model relates to the field of medical apparatus and instruments, and discloses an oxygen-releasing soluble riboflavin microneedle patch for treating keratectasia diseases. The oxygen-releasing soluble riboflavin microneedle patch comprises a patch base and a needle body array, the needle body array comprises a plurality of microneedles, and perfluorodecalin nano emulsion particles are loaded in the microneedles. The soluble microneedle can form reversible micro holes in corneal epithelium, the blocking effect of hydrophobic corneal epithelium on hydrophilic RF is overcome, RF permeation is promoted, meanwhile, O2NE and PFD capable of releasing oxygen are loaded in O2RF-MNs, oxygen can be combined and stored due to the low polarity of fluorine, after the microneedle is dissolved, the O2NE permeates into corneal stroma, and therefore the oxygen release effect of the corneal epithelium on the corneal epithelium on the corneal epithelium on the corneal epithelium on the corneal epithelium on the corneal epithelium on the corneal epithelium is improved. Oxygen is continuously released in the cornea stroma, and no extra device is needed to provide oxygen in the crosslinking process, so that the cornea crosslinking effect is enhanced. In addition, a tiny wound caused by the microneedle on the corneal epithelium can be completely healed within 12 hours, and corneal injury is small.

A method of controlling, limiting or preventing infestation of a crop plant by a phytopathogenic fungus of the genus Fusarium by contacting plant propagation material with a composition comprising riboflavin prior to or during seeding of the crop plant is disclosed.

The invention provides lactobacillus plantarum for high yield of riboflavin and exopolysaccharide under selenium stress and application thereof, and belongs to the technical field of microorganisms, the lactobacillus plantarum is lactobacillus plantarum Vse 252, the Latin name is Lactobacillus plantarum, the lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36123, and the lactobacillus plantarum Vse 252 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The lactobacillus plantarum Vse 252 can convert inorganic selenium into organic selenium or nano-selenium, and the organic selenium or nano-selenium is used for preparing riboflavin under the stress of sodium selenite; the strain not only can normally grow under the stress of high-concentration inorganic selenium, but also can realize efficient conversion from inorganic selenium to organic selenium and nano-selenium based on the strong tolerance, namely strong selenium metabolism capability, and can synchronously produce riboflavin at high yield, thereby having a wide market prospect.

A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

The invention discloses separation and identification of a novel stable drug-resistant tumor cell population SRCC, and relates to the technical field of solid tumor treatment and drug resistance. The novel stable drug-resistant tumor cell SRCC has the characteristics of A) and / or B): A) tumor cells are detected, and if any one or more of riboflavin fluorescence, NOTCH1 and CD82, riboflavin transporter protein, NOTCH1 and CD82 are positive in a tissue sample, the tumor cells are drug-resistant tumor cells; or B) the drug-resistant tumor cells have at least one of the following characteristics: the drug-resistant tumor cells have inherent and stable broad-spectrum drug resistance; the cells are in a resting state; the cell cycle is inhibited; the active oxygen level is high; apoptosis, ferroptosis and programmed necrosis are all inhibited; and an epithelial-mesenchymal transition pathway is inhibited. No matter whether drug treatment exists or not, the drug resistance of the SRCC is inherent and stable, and the SRCC is different from known tumor drug-resistant cell populations.

The application discloses a cell-penetrating riboflavin complex and application thereof in preparation of a photodynamic therapy drug. The riboflavin is coupled with cell-penetrating peptides Arg8, (Cha-Arg)3 and a targeting small molecule triphenylphosphine (TPP) respectively, three complexes of Arg8-RF, (Cha-Arg)3-RF and TPP-RF are designed, and by comparing the cell uptake efficiency and photosensitivity toxicity of the three complexes, (Cha-Arg)3-RF can improve the uptake efficiency of riboflavin by tumor cells, and meanwhile, the photodynamic therapy effect of riboflavin is enhanced. The riboflavin complex can be used to prepare a natural derivative anti-tumor photodynamic therapy drug, and the drug has the advantages of good biocompatibility, low toxicity, and economic availability.

The invention relates to application of probiotics and a composition thereof in improving the quality of cow milk, and belongs to the technical field of food. The lactobacillus mucus CECT5716 or the composition thereof provided by the invention can improve the quality of cow milk, so that the cow milk better meets the requirements of human bodies and calves, and specifically, the improvement of the quality of the cow milk comprises the following steps: increasing the content of immune globulin in the cow milk, improving the composition of fatty acid in the cow milk, increasing the content of riboflavin in the cow milk, and improving the quality of the cow milk. The safety index of the cow milk is improved, and the content of microorganisms and somatic cells in the cow milk is reduced. Meanwhile, the invention also provides a method for improving the quality of cow milk, and the quality of the cow milk is obviously improved by feeding a product containing the lactobacillus mucus CECT5716 to the dairy cow in the perinatal period.

This invention discloses the application of four compounds in regulating the yellow body color of Cordyceps sinensis sclerotia and Hepialus larvae. Specifically, it discloses the application of riboflavin-5'-adenine diphosphate, robinin, 4-hydroxyphenylpyruvic acid, and / or 2-hydroxycinnamic acid in the formation of yellow body color and / or sclerotia color in artificially cultivated Cordyceps sinensis. This invention addresses the problem of poor color (not reaching golden yellow to brownish yellow) of artificially cultured Cordyceps sinensis sclerotia. Injecting riboflavin-5'-adenine diphosphate, robinin, 4-hydroxyphenylpyruvic acid, and 2-hydroxycinnamic acid into the bodies of *Bombyx mori* larvae infected with *Cordyceps sinensis* effectively improves the larvae's body color. Compared to larvae without the injection of these four metabolites, the injected larvae have a deeper and yellower epidermis, indicating that injecting riboflavin-5'-adenine diphosphate, robinin, 4-hydroxyphenylpyruvic acid, and 2-hydroxycinnamic acid into *Bombyx mori* larvae infected with *Cordyceps sinensis* can effectively promote the larvae's epidermis to achieve a yellow body color.

This invention discloses an engineered Bacillus subtilis strain for riboflavin production and its application, belonging to the field of biotechnology; the engineered Bacillus subtilis strain is named ZMBSB H-1, with accession number CCTCC NO: M 20252077; this invention utilizes Bacillus subtilis... Bacillus subtilis Knockout of the genome based on 168 spoOA Genes and ccpA Genes will ribBA‑ribD Mutant gene clusters integrated into spoOA In gene loci, targeted modification purF Mutant gene integration into ccpA In the gene locus, and expressed using the strong promoter P43. ribBA‑ribD Mutant gene clusters and purF The mutated gene was used to construct the Bacillus subtilis engineered strain; the Bacillus subtilis engineered strain can efficiently produce riboflavin using glucose, corn steep liquor powder and yeast extract as substrates.